Mar 01, 2024 8:20am EST Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Feb 16, 2024 4:05pm EST Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Feb 15, 2024 8:00am EST Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jan 11, 2024 8:30am EST Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Jan 09, 2024 8:30am EST Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Jan 04, 2024 9:05am EST Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
